Afynia Laboratories is developing a non-invasive diagnostic tool for endometriosis, targeting the significant issue of chronic pelvic pain and infertility experienced by many women. This technology aims to provide accurate diagnosis without the need for invasive procedures, improving patient outcomes and access to care.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BRFounders
Product
Problem
Endometriosis, a condition affecting a significant number of women, often leads to chronic pelvic pain and infertility. Current diagnostic methods are invasive, posing risks and discomfort to patients, and can delay diagnosis.
Solution
AIMA Laboratories is developing a non-invasive diagnostic tool for endometriosis, offering a less invasive alternative to current diagnostic procedures. This innovative approach aims to provide accurate and timely diagnosis, reducing the need for surgical intervention. By eliminating the need for invasive procedures, AIMA Laboratories seeks to improve patient outcomes, reduce diagnostic delays, and enhance access to care for women experiencing symptoms of endometriosis. The tool is designed to identify the presence of endometriosis through a non-surgical method, potentially leading to earlier intervention and improved management of the condition.
Target Audience
The primary target audience includes women experiencing chronic pelvic pain, period pain, or infertility, as well as healthcare providers specializing in women's health.
Features
- Non-invasive diagnostic method for endometriosis
- Aims to provide accurate results without surgery
- Designed for early detection and timely intervention